Not sure if I believe everything Morning Star publishes and taking this with a very large grain of salt (you may need access to Commsec to view the research report).
They valued MedAdvisor at 82c only a couple days ago (10/03).
https://commsec.api.markitondemand....pdf?access_token=e7klfM2DM5LGCHjYiNBoy8GtRIQF
And increased the valuation to 91c yesterday (11/03).
https://commsec.api.markitondemand....pdf?access_token=e7klfM2DM5LGCHjYiNBoy8GtRIQF
Share price already looks ready for a further tumble following the US last night.
But they have enough of a war chest to ride out this uncertainty without needing to raise capital.
Those companies who may need to chase a CR in this FY might firstly struggle to get the funds they need but also be hit harder because of their financial position.
The recent NPA announcement has started to circulate in the UK.
https://www.pharmacy.biz/new-npa-partnerships-to-benefit-independent-pharmacies/
NPA listed a number of companies under their Business Partners link.
https://www.npa.co.uk/businesspartners/
The above article suggests MedAdvisor is being promoted as the preferred supplier to NPA pharmacies with the other supplier being Healthera.
Healthera only seem to be provide an app (for prescription monitoring and messaging with the pharmacy), whereas MedAdvisor has PlusOne as well as relationships with big pharma for Health Programs.
https://www.healthera.co.uk
Which suggests MedAdvisor only need to have a better platform than Healthera.
Add to My Watchlist
What is My Watchlist?
